Catalyst Pharmaceutical Partners, Inc. Announces Recommendation Of Data Monitoring Committee To Continue Pivotal Phase 3 Clinical Trial For Firdapse™

Published: Mar 25, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CORAL GABLES, Fla., March 25, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase 3 clinical trial evaluating Firdapse™ for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the trial be continued as planned based on the committee's review of safety and clinical data from the trial.

Help employers find you! Check out all the jobs and post your resume.

Back to news